China – based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd (CTTQ) has entered into an exclusive commercial cooperation agreement with compatriot firm Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. Under the terms of the agreement, CTTQ will be responsible for the commercialization of ProteLight’s PL – 5, an antibacterial peptide product used to treat secondary wound infections in China. Financial details of the deal were not disclosed.
About Secondary Wound Infection and PL – 5
Secondary wound infection refers to open wound infections caused by various bacteria, including those associated with diabetic foot ulcers, bedsores, burns, and other conditions. ProteLight’s PL – 5 has successfully concluded a Phase III study in treating secondary wound infections. The product is noted for its wide antibacterial spectrum and its efficacy in treating local open wound infections, particularly those caused by drug – resistant strains. Importantly, PL – 5 does not produce new drug – resistant bacteria, making it a valuable addition to the treatment options for secondary wound infections.
Strategic Implications
The exclusive commercial cooperation agreement between CTTQ and ProteLight highlights the growing focus on innovative treatments for secondary wound infections. By leveraging CTTQ’s commercial capabilities and ProteLight’s advanced antibacterial peptide technology, the partnership aims to improve patient outcomes and address significant unmet medical needs in the treatment of secondary wound infections in China.-Fineline Info & Tech
